C-Path awards $1.7 million to advance five drug development projects
Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).
Read original article on The Medical News →Related news
-
European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease
United Kingdom
-
Recruitment begins for 600 future medical researchers
United Kingdom
-
Virtual reality and music may help lower blood pressure during emergencies
United Kingdom
-
Drone-delivered AEDs could reduce defibrillation delays after cardiac arrest
United Kingdom
-
MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026
United Kingdom
-
UCLA researchers present new radiation advances at ASTRO 2026
United Kingdom
-
AI-based model predicts glioblastoma recurrence to guide targeted treatment
United Kingdom
-
AI-generated video summaries can reshape people's memories of events
United Kingdom